The new head of the US Food and Drug Administration’s generic drugs office suggested their regulatory foundation, the Hatch-Waxman Act, may need some updates to handle the growing number of complex products seeking approval.
Iilun Murphy, who became director of the Office of Generic Drugs on 18 June, said in an interview with Generics...